Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26448837 | 0.98 | CA2 (0.36) | ADORA3FBP1AMDHD2CA2SELP | |
| SCHEMBL30610704 | 0.98 | CA2 (0.36) | ADORA3FBP1AMDHD2CA2SELP | |
| SCHEMBL7948962 | 0.85 | LGALS1 (0.41) | ADORA3FBP1 | |
| SCHEMBL19250987 | 0.83 | LGALS1 (0.44) | FBP1SELPSLC6A2 | |
| SCHEMBL4594966 | 0.82 | CA2 (0.35) | FBP1AMDHD2CA2SELP | |
| SCHEMBL14231358 | 0.82 | CA2 (0.35) | FBP1AMDHD2CA2SELP | |
| SCHEMBL4594969 | 0.82 | CA2 (0.35) | FBP1AMDHD2CA2SELP | |
| SCHEMBL12929290 | 0.81 | ADORA3 (0.36) | ADORA3FBP1SELPFYNMAOA | |
| SCHEMBL12899889 | 0.81 | ADORA3 (0.36) | ADORA3FBP1SELPFYNMAOA | |
| Levoglucose SCHEMBL2007311 | 0.81 | LGALS1 (0.45) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084127-B2 | C2,5′-disubstituted and N6, C2,5′-trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2006-08-01 | — | — | US | disclosed |
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | UNIVERSITEIT LEIDEN (NL) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132686-A1 | C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885FBP1 1084/4885AMDHD2 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.